Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20)
BMJ Open · 2024
DOI: 10.1136/bmjopen-2023-080762 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift BMJ Open, 2024. Verfasst von Masahiro Sekimizu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, NHO Nagoya Medical Center, Nagoya, Japan masahiro.sekimizu@nnh.go.jp. Hauptthemen laut MEDLINE: Methotrexate, Lymphoma, B-Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Themen: Onkologische Pflege, Kinderkrankenpflege
Abstract (Originalsprache)
Introduction Children and adolescents with mature B cell non-Hodgkin lymphoma (B-NHL) are treated with short-intensive chemotherapy. The burden of short-term and long-term toxicity is highly relative to its high cure rate in good-risk patients. Although the addition of rituximab to standard lymphome Malin B (LMB) chemotherapy markedly prolongs event-free survival and overall survival in high-risk patients, the benefit of rituximab in good-risk patients remains to be elucidated. This clinical trial will examine whether the addition of rituximab eliminates anthracyclines in good-risk patients without compromising treatment outcomes. Methods and analysis We will perform a single-arm, open-label, multicentre phase II study. Low-risk (stage I – completely resected, stage II abdominal) and intermediate-risk (stages I and II – incompletely resected; stage II – resected, other than abdominal; stage III with LDH
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, NHO Nagoya Medical Center, Nagoya, Japan masahiro.sekimizu@nnh.go.jp.
- NHO Nagoya Medical Center, Nagoya, Japan.
- Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Department of Pediatrics, Kyushu University, Fukuoka, Japan.
- Department of Pediatrics, Yamagata University Hospital, Yamagata, Japan.
- Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic bomb Survivors Hospital, Hiroshima, Japan.
ORCID-Profile: Masahiro Sekimizu, Hiroya Hashimoto
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Sekimizu, M., Fukano, R., Koga, Y., Mitsui, T., Fujita, N., Mori, T., Hori, D., Tanaka, M., Ohki, K., Iwafuchi, H., Nakazawa, A., Mori, T., Kobayashi, R., Hashimoto, H., M Saito, A., Kamei, M., & Lymphoma Committee of Japan Children’s Cancer Group (2024). Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20). BMJ Open. https://doi.org/10.1136/bmjopen-2023-080762
Vancouver
Sekimizu M, Fukano R, Koga Y, Mitsui T, Fujita N, Mori T, et al. Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20). BMJ Open. 2024. doi:10.1136/bmjopen-2023-080762
BibTeX
@article{Sekimizu2024,
author = {Sekimizu, Masahiro and Fukano, Reiji and Koga, Yuhki and Mitsui, Tetsuo and Fujita, Naoto and Mori, Takeshi and Hori, Daiki and Tanaka, Makito and Ohki, Kentaro and Iwafuchi, Hideto and Nakazawa, Atsuko and Mori, Tetsuya and Kobayashi, Ryoji and Hashimoto, Hiroya and M Saito, Akiko and Kamei, Michi and Lymphoma Committee of Japan Children’s Cancer Group, Lymphoma Committee of Japan Children’s Cancer Group},
title = {Rituximab-combined anthracycline-free chemotherapy in newly diagnosed paediatric and adolescent patients with non-high-risk aggressive mature B cell lymphoma: protocol for a single-arm, open-label, multicentre, phase II study (the Japan Children’s Cancer Group Multicentre Trial, JPLSG B-NHL-20)},
journal = {BMJ Open},
year = {2024},
doi = {10.1136/bmjopen-2023-080762}
}
EUVIMED